Increase of Number of Shares and Votes in Hansa Medical AB (publ)
Lund, Sweden, October 31, 2018 - Hansa Medical AB (NASDAQ Stockholm:HMED), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of October 2018.As previously announced on September 6, 2018. Hansa’s board of directors resolved to issue 391,503 class C shares, by virtue of authorization by the general meeting held on May 29, 2018. Furthermore, the Hansa general meeting resolved to adopt a warrant program